• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

    7/1/25 7:55:51 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JUNS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Silva Alison D.

    (Last) (First) (Middle)
    C/O JUPITER NEUROSCIENCES, INC.
    1001 NORTH US HYWAY 1, SUITE 504

    (Street)
    JUPITER FL 33477

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    JUPITER NEUROSCIENCES, INC. [ JUNS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Pres + Chief Business Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    06/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/02/2025 M 110,227(1) A $0.00 110,227 D
    Common Stock 06/27/2025 P 250 A $1 110,477 D
    Common Stock 06/27/2025 P 100 A $1.035 110,577 D
    Common Stock 06/27/2025 P 250 A $1.0435 110,827 D
    Common Stock 06/27/2025 P 250 A $1.05 111,077 D
    Common Stock 06/30/2025 P 100 A $1.0168 111,177 D
    Common Stock 06/30/2025 P 250 A $1.02 111.427 D
    Common Stock 06/30/2025 P 250 A $1.03 111,677 D
    Common Stock 06/30/2025 P 250 A $1.0368 111,927 D
    Common Stock 06/30/2025 P 100 A $1.0496 112,027 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents restricted stock units which vested on the expiration of the lock-up period.
    /s/ Alison Silva 07/01/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $JUNS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JUNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JUNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 2:53:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/1/25 7:55:51 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    SEC Filings

    See more
    • Jupiter Neurosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      7/10/25 5:08:19 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      7/9/25 4:40:39 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Jupiter Neurosciences Inc.

      10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      5/15/25 4:31:24 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $JUNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

      Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, spotlights the scientific and clinical advantages of its proprietary resveratrol platform, JOTROL™, over conventional resveratrol formulations. Unlocking Resveratrol's Therapeutic Promise Resveratrol is one of the world's most researched molecules and has long been studied for its powerful antioxidant, mitochondrial, and anti-inflammatory effects. However, achieving therapeutic benefit has

      7/23/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

      Nasdaq compliance follows positive upward trend in Company's Stock Price  Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced it has regained compliance with the Nasdaq Stock Market ("Nasdaq") continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disclosed in the Company's Current Report on Form 8-K filed on July 10, 2025. On July 9, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as

      7/10/25 4:05:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

      PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to unveil Nugevia™ PWR, a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance, and recovery. PWR targets a rapidly expanding consumer demand for science-backed, clinically validated supplements, providing a high-margin growth opportunity within the longevity and wellness markets, proje

      6/30/25 3:15:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Pres + Chief Business Officer Silva Alison D.

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/7/25 9:28:07 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Secretary Elmasri Saleem converted options into 66,293 shares (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/7/25 9:28:09 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care